Journals / Mersin Üniversitesi Sağlık Bilimleri Dergisi / 2019 / Cilt: 12 - Sayı: 1

Effects of thalidomide disaster on the development of pharmacovigilance activities

Talidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi

Pages
136–142
Publication Date
2019-04-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, looking at the thalidomide disaster from today’s perspective will help us not only to better understand pharmacovigilance activities but also to identify and solve the challenges that are waiting in the coming years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this review, the effects of thalidomide babies on the development of systematic pharmacovigilance activities were searched with historical perspective.
📊
Key Findings & Data:For this purpose, after PubMed search with relevant keywords, scientific studies that serve our purpose were included and historical information was obtained from the reviews.
💡
Conclusion & Impact:As a result, looking at the thalidomide disaster from today’s perspective will help us not only to better understand pharmacovigilance activities but also to identify and solve the challenges that are waiting in the coming years.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:farmakovijilans · Talidomit · farmakovijilans

Abstract

In this review, the effects of thalidomide babies on the development of systematic pharmacovigilance activities were searched with historical perspective. For this purpose, after PubMed search with relevant keywords, scientific studies that serve our purpose were included and historical information was obtained from the reviews. Our results underlied the fact that thalidomide disaster was the main driving force for the development of important pharmacovigilance activities such as teratogenicity, ethical and legal regulations on drug safety, drug development and post-marketing drug surveillance. Currently, the return of thalidomide in the treatment of cutaneous leprosy and multiple myeloma has changed our view on drug safety and highlighted the importance of risk management. As a result, looking at the thalidomide disaster from today’s perspective will help us not only to better understand pharmacovigilance activities but also to identify and solve the challenges that are waiting in the coming years.

Özet

Bu derlemede, tarihsel bir yaklaşımla, talidomit kullanan gebelerin fokomelili bebeklerinin doğumu sonrasında yaşananlar değerlendirilerek, bu facianın sistematik farmakovijilans etkinliklerinin gelişimine etkisi araştırılmıştır. Bu amaçla, ilgili anahtar kelimeleri içeren PubMed taraması yapılarak çalışmamızın amacı ile uyumlu bilimsel makaleler ve tarihsel bilgileri içeren derlemeler çalışmamıza dahil edilmiştir. Bulgularımız teratojenisite, ilaç güvenliliği ile ilgili etik ve yasal düzenlemeler, ilaçların geliştirilmesi ve pazarlama sonrası gözetimi gibi önemli farmakovijilans etkinliklerinin gelişiminde talidomit faciasının nasıl bir itici güç olduğunu vurgulamıştır. Talidomidin kütanöz lepranın ve multipl myelomanın tedavisinde kullanılmak üzere yakın geçmişte ilaç piyasasına geri dönüşü ilaç güvenliliğine bakış açımızı değiştirmiş ve risk yönetimini ön plana çıkartmıştır. Sonuç olarak; talidomit faciasının ardından yaşananlara günümüzün gözüyle bakmak, farmakovijilans etkinliklerini daha iyi anlamamızı sağlamakla birlikte önümüzdeki yıllarda farmakovijilansı bekleyen zorlukları belirleyip çözmemize yardımcı olma potansiyelini de taşımaktadır.

🔖

Cite This Article

BUHARALIOĞLU, C. K., BUHARALIOĞLU, G. Y. (2019). Effects of thalidomide disaster on the development of pharmacovigilance activities. Mersin Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 12 - Sayı: 1, 136–142. https://ajindex.com/articles/92819

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. World Health Organization. The Importance of Pharmacovigilance. Erişim yeri: http://apps.who.int/medicinedocs/en/d/Js4893e/, Erişim tarihi: 2.10.2018
  2. Pharmacovigilance Risk Assessment Committee: PRAC strategy on measuring the impact of Pharmacovigilance activities. Erişim yeri: http://www.ema.europ a.eu/docs/en_GB/docum ent_libra ry/Other/2016/01/WC500 19975 6.pdf, Erişim tarihi: 2.10.2018
  3. James HK, Anthony RS. Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease. Tox Sci 2011;122(1); 1–6
  4. Mellin GW, Katzenstein M. The saga of thalidomide: neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962; 267: 1184–92
  5. Vargesson N. The teratogenic effects of thalidomide on limbs. J Hand Surg Eur 2018 Vol. 2018; 1753193418805249
  6. Schumacher HA. Comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 1968; 160; 189–199
  7. McFadyen R. Thalidomide in America: A brush with tragedy. Clio Medica 1976; 11: 79-93
  8. Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38: 203–15
  9. Smithells RW, Newman CHG. Recognition of thalidomide defects. J Med Genet 1992; 29:716-723
  10. Lenz W, Knapp K. Foetal malformations due to Thalidomide. German Med 1962;7:253–8
  11. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961; ii:1358
  12. Curran, W. The thalidomide tragedy in Germany: The end of a historic medicolegal trial. New Engl J Med, 1971; 284: 481-482
  13. Kelsey, F. Thalidomide update: regulatory aspects. Teratology 1988; 38: 221–226
  14. Lenz, W. Malformations caused by drugs in pregnancy. Am J Dis Child, 1966; 112: 99-106
  15. Lenz W. 1962. Thalidomide and congenital abnormalities [letter]. Lancet 279:303–305
  16. Newman CGH. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol 1986; 13:555-573
  17. Vargesson N. Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today 2015; 105: 140 – 156
  18. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303–306
  19. Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis 1969; 37: 135–146
  20. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085
  21. Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related m